A Multicentre, Randomised, Double-blind, Placebo-controlled, 2-way Cross-over Study to Evaluate the Efficacy and Safety of CHF 5259 (Glycopyrrolate Bromide) pMDI on Top of QVAR pMDI for the Treatment of Patients With Uncontrolled Asthma on Low-Medium Dose of Inhaled Corticosteroids

Trial Profile

A Multicentre, Randomised, Double-blind, Placebo-controlled, 2-way Cross-over Study to Evaluate the Efficacy and Safety of CHF 5259 (Glycopyrrolate Bromide) pMDI on Top of QVAR pMDI for the Treatment of Patients With Uncontrolled Asthma on Low-Medium Dose of Inhaled Corticosteroids

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Glycopyrrolate (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms ELITRA
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 15 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 13 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials
    • 05 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top